BIOMAT Database Logo BIOMAT Database Logo

Paclitaxel-anthracycline combination chemotherapy in relapsing advanced ovarian cancer after platinum-based chemotherapy: a pilot study. 1998

J E Kurtz, and G Deplanque, and B Duclos, and F Eichler, and C Giron, and J M Limacher, and R Herbrecht, and F Maloisel, and F Oberling, and J P Bergerat, and P Dufour
Department of Onco-Hematology, Hôpitaux Universitaires, Strasbourg, 67098, France.

Despite high response rates with platinum-based front-line chemotherapy, the prognosis for advanced ovarian carcinoma (AOC) is poor. Salvage chemotherapy for recurrent AOC was of little benefit before paclitaxel as single-agent therapy showed appreciable efficacy. Anthracyclines are effective, but are not often part of first-line therapy. In this pilot study, we investigated the feasibility of an anthracycline plus paclitaxel combination therapy for recurrent AOC. Twenty-four patients received 150 mg/m2 paclitaxel on day 1, with either 50 mg/m2 doxorubicin on day 1 or 75 mg/m2 epirubicin on day 1 every 3 weeks. A 27% overall response rate was obtained. Myelosuppression was the major toxicity, but was manageable. No myocardiac toxicity was observed. We conclude that paclitaxel-anthracyclines is a promising salvage combination therapy in AOC that should be investigated further.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J E Kurtz, and G Deplanque, and B Duclos, and F Eichler, and C Giron, and J M Limacher, and R Herbrecht, and F Maloisel, and F Oberling, and J P Bergerat, and P Dufour
Taxane/platinum/anthracycline combination therapy in advanced epithelial ovarian cancer.
February 1997, Seminars in oncology,
J E Kurtz, and G Deplanque, and B Duclos, and F Eichler, and C Giron, and J M Limacher, and R Herbrecht, and F Maloisel, and F Oberling, and J P Bergerat, and P Dufour
Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
September 2021, International journal of urology : official journal of the Japanese Urological Association,
J E Kurtz, and G Deplanque, and B Duclos, and F Eichler, and C Giron, and J M Limacher, and R Herbrecht, and F Maloisel, and F Oberling, and J P Bergerat, and P Dufour
A pilot study of three-cycle consolidation chemotherapy with paclitaxel and platinum in epithelial ovarian cancer patients with clinical complete response after paclitaxel and platinum chemotherapy.
January 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
J E Kurtz, and G Deplanque, and B Duclos, and F Eichler, and C Giron, and J M Limacher, and R Herbrecht, and F Maloisel, and F Oberling, and J P Bergerat, and P Dufour
Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients.
January 1996, Oncology,
J E Kurtz, and G Deplanque, and B Duclos, and F Eichler, and C Giron, and J M Limacher, and R Herbrecht, and F Maloisel, and F Oberling, and J P Bergerat, and P Dufour
A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study.
January 2001, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
J E Kurtz, and G Deplanque, and B Duclos, and F Eichler, and C Giron, and J M Limacher, and R Herbrecht, and F Maloisel, and F Oberling, and J P Bergerat, and P Dufour
Is platinum-based chemotherapy with paclitaxel effective in optimally debulked patients with advanced ovarian cancer?
July 2001, European journal of obstetrics, gynecology, and reproductive biology,
J E Kurtz, and G Deplanque, and B Duclos, and F Eichler, and C Giron, and J M Limacher, and R Herbrecht, and F Maloisel, and F Oberling, and J P Bergerat, and P Dufour
Platinum-based neoadjuvant chemotherapy for advanced ovarian cancer.
July 2007, Gynecologic oncology,
J E Kurtz, and G Deplanque, and B Duclos, and F Eichler, and C Giron, and J M Limacher, and R Herbrecht, and F Maloisel, and F Oberling, and J P Bergerat, and P Dufour
Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial.
January 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
J E Kurtz, and G Deplanque, and B Duclos, and F Eichler, and C Giron, and J M Limacher, and R Herbrecht, and F Maloisel, and F Oberling, and J P Bergerat, and P Dufour
Editorial Comment to Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
September 2021, International journal of urology : official journal of the Japanese Urological Association,
J E Kurtz, and G Deplanque, and B Duclos, and F Eichler, and C Giron, and J M Limacher, and R Herbrecht, and F Maloisel, and F Oberling, and J P Bergerat, and P Dufour
Chemotherapy of advanced ovarian carcinoma: initial experience using a platinum-based combination.
May 1982, Cancer,
Copied contents to your clipboard!